stockrow
Saturday 7 November 2026
Export GLUE’s income statement to Excel — free account
Monte Rosa Therapeutics, Inc.
GLUE Healthcare Biotechnology
Monte Rosa Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $123.7 million, up 63.5% from fiscal 2024.
- Revenue
- +325.8%
- EPS
- +109.1%
- Free cash flow
- −142.6%
Quarter to September 2026, against a year earlier
10.49
0.24
+2.34%
Follow GLUE
Alert me
Monte Rosa Therapeutics, Inc. (GLUE) P/E ratio
Monte Rosa Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 66.6× (April 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 66.6×
Ten-year median
0.0×
Current reading's percentile
72
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GLUE Monte Rosa Therapeutics, Inc. | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.4× |
| PHAR Pharming Group N.V. Sponsored ADR compare | 34.2× |
| LTGO Latigo Biotherapeutics Inc compare | — |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)